CAR T Cells Produce 10-Year Remissions in Some With Lymphoma

Published Date: 25 Jun 2026

Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.

Read Full News

Latest News

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

New Immune Therapy Boosts Disease Control in Prostate Cancer

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

Multiple Myeloma Patients Have Unequal Access to Treatment

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

e-Cigarettes and Lung Cancer: Is Harm Reduction Overstated?

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

Todays Updates

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

Drug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.

Todays Updates

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

Drug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.

Latest News

Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

Simple well-timed prompts to clinicians and patients with advanced cancer can increase conversations around care goals, but clear documentation remains a challenge.

An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.

Lack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.

A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.

News All Time

Breast Cancer Genetic Testing Need in Black Women Identified

A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.

NHS Offers Targeted Radiotherapy for Early Prostate Cancer

Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.

Smartphone App Detects Eye Cancers From Photos

A smartphone app that analyzes images of the eye may enable early screening for cancers of the eye surface, flag lesions at high risk for specialist review, and expand access beyond clinics.

Novel ADC Improves Survival in Metastatic TNBC

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Researchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Snus Linked to Gingival Damage, Raising Safety Questions

Research shows that snus and newer oral nicotine pouches are associated with localized soft tissue changes, prompting greater attention to their oral health effects.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Teclistamab Alone Ups Previously Treated Myeloma Survival

In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.

Therapy Combo Improves Radiographic PFS in Prostate Cancer

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Abemaciclib Slows Progression of Advanced Liposarcoma

In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.

Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets

In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.

FDA Approves Novel Targeted Therapy for Rare Blood Cancer

The CD123-directed antibody and alkylating agent conjugate led to complete remission or clinical complete remission in nearly 70% of treatment-naive patients in a single arm study.

Recommended News For You

Neural networks and label-free microscopy enable accurate detection of pancreatic tumors

'Chemo brain' cognitive issues linked to poor lymphatic-system drainage

Clinical trial could lead to new 'gold standard' test for prostate cancer detection

CAR T Cells Produce 10-Year Remissions in Some With Lymphoma

Mezigdomide Combinations Show Promise in Multiple Myeloma

Biocomputer From Human Neurons Plays Doom, Raises Ethics

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

Recommended Articles For You

Tumor Microenvironment Mapping in Cancer Care 

Bone Marrow Niche Dysregulation in Hematologic Disorders 

Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment 

The Latest Research on Wiskott Aldrich Syndrome  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Exercise may help breast cancer survivors manage weight

2.

US to Loosen Marijuana Rules in Major Shift for $47 Billion Industry

3.

Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment

4.

Opposition to the Surgical Lymph Node Sampling Rule for Lung Resection.

5.

Adjuvant Radiation Boosts High-Risk Bladder Cancer Control

1.

Environmental Carcinogen Exposure Risk Modeling: Current Evidence and Clinical Implications

2.

Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment

3.

Exploring the Causes and Treatment of Granulocytopenia: A Comprehensive Guide

4.

Exploring The Causes and Consequences of Low Transferrin Saturation

5.

The Life-Saving Powers of Anemia: How to Combat the Disease.

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI

3.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

4.

Navigating the Complexities of Ph Negative ALL - Part VII

5.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot